Bioequivalence study of lercanidipine 10 mg tablets?

A bioequivalence study of lercanidipine 10 mg tablets assesses whether the generic formulation of this antihypertensive medication has comparable bioavailability to the branded version. This involves administering both formulations to healthy volunteers under controlled conditions and measuring the concentration of the drug in the bloodstream over time. Key pharmacokinetic parameters, such as peak plasma concentration (Cmax) and the area under the curve (AUC), are then compared. Regulatory agencies require such studies to ensure that generic drugs are therapeutically equivalent to their brand-name counterparts.